Parkinson's Disease Therapeutics Help In Restoring The Production Of Dopamine In The Brain Which Leads To Reducing Other Symptoms Of The Disease

 

Most people who have Parkinson’s Disease Therapeutic have significant improvement in symptoms after they start taking medicines. The drugs work by restoring the production of dopamine in the brain. They may also reduce other symptoms of the condition, such as stiffness and slowness, as well as improve cognition and mood.

Many of these medications are used in combination to maximize their effectiveness and reduce side effects. Levodopa and carbidopa, or Lodosyn, are commonly prescribed to treat tremors and other motor symptoms of Parkinson's. Amantadine is sometimes used along with these medications to control writhing, uncontrolled movements called dyskinesia.

Similar to ablative surgery, deep brain stimulation temporarily disables the overactive cells that cause symptoms of Parkinson’s Disease Therapeutic by sending pulses of electricity into specific areas in the brain. This therapy can provide relief of tremor and other symptoms for some people, whereas it does not keep the disease from progressing.

Some people with advanced Parkinson’s Disease Therapeutic who have trouble controlling their tremor, rigidity or other movement problems may be a good candidate for surgery to control symptoms. Ablative surgery, transplantation of dopamine-producing cells to the brain and stimulation surgery are types of surgeries that can be performed.

For a small number of patients, radiofrequency energy currents can be used to destroy a specific portion of the thalamus in the brain, which can help with disabling tremor in the hands or arms. The procedure is usually used in younger patients with essential tremor, not in older patients with Parkinson's.

For moderate to severe cases of Parkinson's that don't respond well to medications, focused ultrasound is a potential new approach. A single session of this technique, in which the pulse generator is inserted into the brain and a tiny electric current is sent to certain areas, can provide effective and long-lasting relief from tremors.

Recently formed as a partnership between two Michigan State University researchers and the MSU Innovation Center, CavGene Therapeutics has a first goal of developing a gene therapy to improve care for patients with Parkinson's.

In the past, scientists have tried various treatments for Parkinson's disease, including gene therapy and transplantation of dopamine-producing brain cells. However, the results have been inconsistent and often unreliable.

Fortunately, clinical trials have led to the development of many effective medications and new techniques for using them. The success of these therapies depends on the involvement of patients and their doctors.

STADA has acquired the rights to a triple combination product which consists of active ingredients like carbidopa, entacapone and levodopa. In February 2021, it was launched in Austria and Germany for treating advanced Parkinson's disease.